Luke W. Chen

Luke W. Chen

Auto-generated profile, based on publicly available information

Luke W. Chen

Brigham and Women's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in The Eurasian Journal of Medicine
Verified
Journal Article
Open access
TWTyler Walburn
Tyler Walburn
Yetkin TuaçYetkin Tuaç
Yetkin Tuaç
CACagdas AKTAN
Cagdas AKTAN
OAOkan Argun
Okan Argun
LCLuke W. Chen
Luke W. Chen
MSMutlay Sayan
Mutlay Sayan
Background: Although extensive research highlights the detrimental effect of cribriform pattern 4 (CP4) on survival in non-high-risk prostate cancer (PC), its prognostic significance in high-risk PC is not well understood. Methods: The individual patient data from the The Cancer Genome Atlas (TCGA) database following radical prostatectomy was retrospectively examined. A predefined statistical analysis was conducted to evaluate the potential association between CP4 and progression-free survival (PFS). Results: Of the 135 patients examined, CP4 was present in 66 (48.9%). Median follow-up was 45.93 months (interquartile range: 22.87, 80.10). Cribriform pattern 4 was associated with a significantly reduced PFS (subdistribution hazard ratio, 1.99; 95% CI, 1.01-3.92; P = .045) following adjustment for covariates. Conclusions: The presence of CP4 in high-risk Gleason 8-10 PC portends worse PFS. Further studies are warranted to fully understand its implications in risk stratification and post-operative management of PC. Cite this article as: Walburn T, Tuac Y, Aktan C, et al. Impact of cribriform pattern on progression-free survival after radical prostatectomy in gleason score 8-10 prostate cancer. Eurasian J Med. 2025; 57(1), 0804 doi: 10.5152/eurasianjmed.2025.25804.

25 September 2025 in bioRxiv
Verified
Preprint
Open access
EGEmma M. Garcia
Emma M. Garcia
OLOlivia R. Lavidor
Olivia R. Lavidor
SRShaunak Raval
Shaunak Raval
NLNicholas Z. Lue
Nicholas Z. Lue
JLJessica K. Liang
Jessica K. Liang
BLBrian B. Liau
Brian B. Liau
Summary: DNA methyltransferase 3A (DNMT3A) is a de novo DNA methyltransferase that is recurrently mutated in hematological malignancies and developmental disorders. The most prevalent mutation, R882H, compromises DNMT3A activity in a dominant-negative manner, but its precise biochemical mechanism has been debated. Here, we use paired deep mutational scanning of the wild-type and R882H-mutant proteins to systematically identify mutations on a massively parallel scale that modify DNMT3A activity by suppressing, phenocopying, or selectively rescuing the dominant-negative effect of R882H. By leveraging the mutational depth and unbiased nature of the paired genetic landscapes, we uncover two distinct mechanisms that can rescue DNMT3A R882H activity, providing novel insights into the function of the R882 hotspot. First, by analyzing the effects of combinatorial mutations in the target recognition domain (TRD), we reveal that its crosstalk with the ADD regulatory domain modulates DNMT3A DNA binding and enzymatic activity, partially compensating for R882H-induced loss-of-function. Second, pairwise analysis of variant effects across the two genetic backgrounds supports the notion that R882H promotes aberrant macro-oligomerization of DNMT3A via its central dimerization interface, which accounts for its dominant-negative effect. Critically, we show that the R882 position exhibits a distinct dominant-negative signature in the genetic landscape, where positively charged residues at this position safeguard against aberrant macro-oligomerization. By performing hydrogen-deuterium exchange mass spectrometry (HDX-MS) on DNMT3A mutants, we show that R882H dramatically alters the protein dynamics of DNMT3A, rigidifying its central dimerization interface to promote oligomerization. Our data support a new model in which R882H removes the critical function of R882, where the arginine attenuates the pre-organization of the interface and subsequent oligomerization at a supramolecular assembly hotspot 1 . Altogether, we map the genetic landscape underpinning the DNMT3A R882H hotspot mutation, illuminating the unexpected molecular mechanism of macro-oligomerization that drives its dominant-negative effect.

1 May 2025 in JCO Global Oncology
Verified
Journal Article
Closed access
JPJames Parisi
James Parisi
Yetkin TuaçYetkin Tuaç
Yetkin Tuaç
OAOkan Argun
Okan Argun
GKGarrett Kearney
Garrett Kearney
LCLuke W. Chen
Luke W. Chen
MSMutlay Sayan
Mutlay Sayan
PURPOSE: Prostate cancer poses a significant public health challenge in the Middle East, with advanced-stage diagnoses and high mortality rates. However, projections regarding its future incidence are limited. The aims of this study were to estimate prostate cancer incidence in the region through 2050, to evaluate socioeconomic factors contributing to regional disparities, and to provide insights to inform future health care policies and resource allocation. METHODS: Data from the Global Cancer Observatory were analyzed for Middle Eastern countries, with Europe and North America included for comparison. The percentage change in incidence between 2022 and 2050 was compared across regions using the Mann-Whitney U test. Additional subgroup analyses based on income level and Human Development Index were performed using Kruskal-Wallis test. Spearman rank correlation was used to explore the association between incidence trends and socioeconomic indicators. RESULTS: In 2022, Middle Eastern countries reported 50,944 patients with newly diagnosed prostate cancer, accounting for 3.47% of global incidence. The projected increase in prostate cancer incidence by 2050 was significantly higher in the Middle East compared with Europe and North America (mean rank, 12.50 v 1.50; P = .009). Higher income countries exhibited a greater percentage increase ( P = .033), and the income level correlated positively with incidence trends ( r = 59.6%; P = .006). Countries with increasing incidence rates had a markedly higher percentage change than those expected to decline ( P = .031). CONCLUSION: Prostate cancer incidence in the Middle East is expected to rise substantially by 2050, with socioeconomic disparities influencing disease trends. These findings highlight the urgent need for targeted awareness campaigns, improved screening strategies, enhanced oncology infrastructure, and strengthened cancer registries to mitigate the projected burden and improve outcomes in the region.